Ananda Pharma Income Statement

Financials in millions GBP. Fiscal year is February - January.

Millions GBP. Fiscal year is Feb - Jan.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Jul '24 Jul 31, 2024	Jan '24 Jan 31, 2024	Jan '23 Jan 31, 2023	Jan '22 Jan 31, 2022	Jan '21 Jan 31, 2021	Jan '20 Jan 31, 2020	2019
Selling, General & Admin	1.69	1.78	0.84	0.97	0.5	0.38	Upgrade
Operating Expenses	3.09	2.97	1.01	0.97	0.5	0.38	Upgrade
Operating Income	-3.09	-2.97	-1.01	-0.97	-0.5	-0.38	Upgrade
Interest Expense	-0.24	-0.14	-0.25	-	-	-	Upgrade
Interest & Investment Income	0	0	-	-	0	0.01	Upgrade
Currency Exchange Gain (Loss)	-	-	-	-0	0	-0.01	Upgrade
EBT Excluding Unusual Items	-3.33	-3.11	-1.26	-0.97	-0.5	-0.37	Upgrade
Impairment of Goodwill	-1.01	-1.01	-	-	-	-	Upgrade
Asset Writedown	-2.81	-2.81	-0.04	-	-	-	Upgrade
Pretax Income	-7.16	-6.93	-1.3	-0.97	-0.5	-0.37	Upgrade
Income Tax Expense	-0.78	-0.78	-	-	-	-	Upgrade
Net Income	-6.37	-6.15	-1.3	-0.97	-0.5	-0.37	Upgrade
Net Income to Common	-6.37	-6.15	-1.3	-0.97	-0.5	-0.37	Upgrade
Shares Outstanding (Basic)	3,529	2,631	851	722	446	386	Upgrade
Shares Outstanding (Diluted)	3,529	2,631	851	722	446	386	Upgrade
Shares Change (YoY)	179.44%	209.17%	17.94%	61.94%	15.39%	17.31%	Upgrade
EPS (Basic)	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	Upgrade
EPS (Diluted)	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	Upgrade
Free Cash Flow	-	-0.72	-0.46	-	-	-0.51	Upgrade
Free Cash Flow Per Share	-	-0.00	-0.00	-	-	-0.00	Upgrade
EBITDA	-2.34	-2.41	-0.84	-	-	-	Upgrade
D&A For EBITDA	0.75	0.56	0.17	-	-	-	Upgrade
EBIT	-3.09	-2.97	-1.01	-0.97	-0.5	-0.38	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.